While the reduction in price target from $109 to $106 by Mizuho could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Graig Suvannavejh suggests a continued positive outlook on Axsome Therapeutics. The slight decrease in the price target might reflect adjustments in valuation models or market conditions, but the overall recommendation remains bullish. This mixed signal could lead to a neutral short-term impact on AXSM's stock price, as investors weigh the lowered price target against the reaffirmed confidence in the company's prospects.